Bayer said it asked the FDA to allow this in response to iodinated contrast media shortages caused by supply pressures resulting from COVID-19 lockdowns in China. The imported stock is manufactured at the same site that manufactures the iopromide in Berlin.

The iopromide injection is approved only for intra-arterial and intravenous administration and not for intrathecal use. The company is directing people to the U.S. Prescribing Information page for more information.